New hope for advanced breast cancer: experimental combo enters phase 3 trial
NCT ID NCT07518173
First seen Apr 09, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This phase 3 trial tests a new drug, BL-M07D1, combined with pertuzumab against the standard treatment (docetaxel, trastuzumab, and pertuzumab) in 596 women with HER2-positive breast cancer that has spread or returned. The goal is to see if the new combo delays cancer growth or improves survival. Participants must not have had prior treatment for advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Contact
Contact
Contact
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact
Conditions
Explore the condition pages connected to this study.